<DOC>
	<DOCNO>NCT01684449</DOCNO>
	<brief_summary>The soft tissue sarcoma ( STS ) constitute infrequent group malignant neoplasm mesenchymal origin . In Spain , approximate incidence 2 new case per 100.000 inhabitant every year . In patient metastatic STS , average survival short , approximately 12 month . The systemic treatment metastatic disease limit development , satisfactory result . This facts reflect urgent need identify new active agent treatment patient . The molecular pathway serine/threonine kinase mammalian target rapamycin ( mTOR ) play central role regulation proteins translation , cellular growth metabolism ( Meric-Bernstam F et al . 2009 ) . Currently , mTOR pathway consider relevant target development anti-cancer drug , rapamycin . Preliminary result clinical trial suggest mTOR inhibitor could clinical activity different type sarcoma , include STS ( Chawla et al Proc.ASCO 2006 ; Schuetze et al . Proc.ASCO 2006 ) . Gemcitabine chemotherapy antimetabolite agent broad antitumoral spectrum . The activity drug treat resistant sarcoma reduce toxicity make gemcitabine adequate candidate study combination new drug address molecular target STS treatment . Pre-clinical study suggest mTOR inhibitor could potential synergistic additive effect chemotherapy agent . The combination rapamycin gemcitabine seem reasonable strategy explore STS treatment .</brief_summary>
	<brief_title>Gemcitabine Plus Rapamycin Versus Gemcitabine Treat Advanced Soft Tissue Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Patients anatomopathological diagnosis metastatic locally advanced unresectable soft tissue sarcoma ( STS ) . Patients follow STS type exclude : chondrosarcoma , Ewing 's sarcoma embryonal alveolar rhabdomyosarcoma . In phase 1 allow include patient type advance cancer resistant standard treatment benefit study drug . 2 . Prior treatment chemotherapy include doxorubicin ifosfamide , contraindication administration . The previous treatment gemcitabine inhibitor mTOR allow . 3 . Age ≥ 18 ≤ 70 year . 4 . ECOG performance status : 0 1 . In Phase 1 patient ECOG 01 enrol . 5 . Disease measurable accord RECIST criterion . Proven relapse disease . 6 . Adequate bone marrow function , define neutrophil count ≥ 1.500/mm^3 platelet ≥ 100.000/mm^3 . 7 . Adequate renal hepatic function , define calculated creatinine clearance ≥ 60 ml/min , creatinine , total bilirubin , AST and/or ALT ≤ 1,5 time upper limit normal ( ULN ) . 8 . Informed consent form sign patient prior begin treatment . 1 . History previous cancer diagnose treat past 5 year except basal cell carcinoma , cervical carcinoma situ superficial bladder cancer . 2 . Presence brain metastasis . 3 . Active infection severe concomitant disease . 4 . Concurrent treatment experimental drug within 30 day prior study entry . 5 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Soft tissue sarcoma</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Rapamycin</keyword>
	<keyword>Sirolimus</keyword>
	<keyword>mTOR inhibitor</keyword>
	<keyword>Molecular biomarkers</keyword>
</DOC>